JP Morgan Chase
ARQT icon

JP Morgan Chase’s Arcutis Biotherapeutics ARQT Stock Holding History

JP Morgan Chase’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-45,000
Closed -$1.23M – 6464
2021
Q2 		$1.23M Sell
45,000
-65,500
-59% -$1.84M ﹤0.01% 4156
2021
Q1 		$3.2M Buy
+110,500
New +$3.45M ﹤0.01% 3346

Other funds holding ARQT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

JP Morgan Chase's ARQT Position: Q2 2026 in Review

JP Morgan Chase reduced its Arcutis Biotherapeutics (ARQT) stake by 13% in Q2 2026, selling an estimated $349K and leaving 97,966 shares worth $2.76M. The position accounts for ﹤0.01% of the portfolio, ranked #3943.

JP Morgan Chase first reported a position in ARQT in Q1 2020 and has held it in 26 quarters since. The position peaked at $15.9M in Q4 2024. 183 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • JP Morgan Chase held 97,966 shares of Arcutis Biotherapeutics worth $2.76M as of Q2 2026.
  • JP Morgan Chase sold 14,988 Arcutis Biotherapeutics shares in Q2 2026, an estimated $349K.
  • Arcutis Biotherapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #3943 holding.
  • JP Morgan Chase first reported a position in Arcutis Biotherapeutics in Q1 2020 and has held it in 26 quarters since.
  • JP Morgan Chase's Arcutis Biotherapeutics position peaked at $15.9M in Q4 2024.
  • 183 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.